Initiation of smoking occurs during adolescence. Some studies found that adolescent rats develop self-administration at higher nicotine doses than adults. For the same nicotine dose, adolescents have lower plasma nicotine levels than adults, suggesting they may have faster nicotine metabolism which may contribute to the differences in nicotine-induced behaviours. This study investigated the developmental differences in rat hepatic CYP2B protein expression, in vivo and in vitro nicotine metabolism. Plasma and brain nicotine levels were lower in early-adolescents than adults, however, cotinine levels were also lower. Slower rates of cotinine formation in early-adolescents may explain their lower cotinine levels. Early-adolescents express higher total CYP2B proteins than adults, but they appear to have less of CYP2B1, the nicotine metabolizing enzyme. These findings provide a better understanding of this animal model and indicate that differences in pharmacokinetics should be considered when comparing nicotine’s effects in adolescents and adults extrapolating behavioural findings to human.

Initiation of smoking occurs during adolescence. Some studies found that adolescent rats develop self-administration at higher nicotine doses than adults. For the same nicotine dose, adolescents have lower plasma nicotine levels than adults, suggesting they may have faster nicotine metabolism which may contribute to the differences in nicotine-induced behaviours. This study investigated the developmental differences in rat hepatic CYP2B protein expression, in vivo and in vitro nicotine metabolism. Plasma and brain nicotine levels were lower in early-adolescents than adults, however, cotinine levels were also lower. Slower rates of cotinine formation in early-adolescents may explain their lower cotinine levels. Early-adolescents express higher total CYP2B proteins than adults, but they appear to have less of CYP2B1, the nicotine metabolizing enzyme. These findings provide a better understanding of this animal model and indicate that differences in pharmacokinetics should be considered when comparing nicotine’s effects in adolescents and adults extrapolating behavioural findings to human.

N-methyl D-aspartate (NMDA) receptors represent integral signal transducers for excitatory glutamate neurotransmission. While NMDA receptors are critical for synaptic plasticity, the molecular events underlying this process are not fully elucidated. The potential role of NP22, a novel neuronal protein, as a downstream mediator of NMDA receptor function is explored. NP22 protein expression in genetic and pharmacological models of NMDA receptor hypofunction is examined and no significant changes are reported. Characterization of the NP22 protein complex via tandem-affinity and FLAG-purification coupled with mass spectrometry was used and no novel protein interactions are reported. GFP-tagged NP22 colocalization with F-actin decreases in cell processes of transiently transfected HEK293 cells in response to elevated intracellular calcium, while similar colocalization reductions are not seen in stably transfected HEK293 under a comparable treatment regiment. Changes in intracellular calcium affecting NP22 biology can be useful in the ongoing characterization of this novel protein.

Propofol is a widely in use anesthetic drug. Propofol’s abuse liability has been supported by many case reports and a few animal studies. However, propofol’s reinforcing properties have not yet been investigated in-depth. In this study, multiple aspects of propofol’s abuse-related behaviour were investigated using the drug self-administration model in rats. METHODS: Rats were subjected to propofol self-administration under a fixed ratio 1 (FR1) schedule and different aspects of propofol self-administration behaviour including acquisition, maintenance of the behaviour under a higher ratio schedule, extinction and reinstatement were investigated. RESULTS: Rats acquired propofol self-administration under a FR1 schedule. The acquired behaviour was maintained under a FR2 schedule, showed a modest variation over a range of doses, and was extinguished upon substitution of vehicle for propofol, showing no reinstatement using a range of priming doses of propofol. CONCLUSION: Propofol has abuse potential showing modest reinforcing properties under our experimental conditions.

TiPARP is a PARP-like mART that is induced by and negatively regulates AHR transactivation. Despite these insights, not much is known about TiPARP. This study aimed to characterize the regulation of TiPARP by AHR, PDGFR, and ERα, and investigate potential receptor interplay. Gene expression studies revealed that coactivation of AHR and PDGFR can enhance TiPARP expression after 3 h relative to activation of either receptor pathway alone. Gene expression and ChIP studies demonstrated that while co-activation of AHR and ER enhanced AHR, ARNT, and ERα recruitment to the regulatory region of TiPARP, TiPARP mRNA levels were not potentiated by co-activation relative to activation of either pathway. Dissection of the 5’ regulatory region of TiPARP using reporter gene assays revealed that a putative AHRE cluster and an ERE half-site were functional. Lastly, overexpression of TiPARP with an estrogen-responsive reporter revealed that TiPARP can repress ERα signalling and requires its catalytic activity.

Anxiety is a highly prevalent comorbidity in coronary artery disease (CAD) and confers increased risk of subsequent cardiac events and mortality. However, biological mechanisms of this relationship are not well understood. Ceramides are sphingolipids involved in inflammatory signaling and cell viability in the periphery and nervous system, and are implicated in pathophysiological mechanisms associated with anxiety. This study aimed to investigate relationships between plasma ceramide concentrations and anxiety symptomology as assessed by the Spielberger State-Trait Anxiety Inventory trait subscale (STAI-T) in CAD patients with linear regressions. High performance liquid chromatography coupled electrospray ionization tandem mass spectrometry was used to assay sphingolipid species. Plasma C22:0 ceramide (β=-0.232, p=0.018) concentrations and 8 other species of sphingolipids (SM18:0, SM20:1, C18:0, C20:0, C18:1, DHC22:0, LacC22:0, LacC24:1) were negatively correlated with STAI-T score when controlling for gender, BMI, and CES-D. Findings suggest specific sphingolipids to be potential markers for anxiety severity in CAD.

Deep brain stimulation (DBS) has emerged as a potential intervention for treatment-resistant tardive dyskinesia (TD). Despite promising case reports, no consensus exists regarding optimal stimulation parameters, neuroanatomical target for DBS in TD, or mechanisms underlying its anti-dyskinetic effects. We used vacuous chewing movements (VCMs) in rats treated chronically with haloperidol (HAL) as a TD model to address some of these issues. We show that acute DBS applied to the subthalamic nucleus (STN) or the entopeduncular nucleus (EPN) suppresses VCMs without affecting locomotor activity. Using immediate early gene mapping with zif268 as an index of neuronal activity, we found that STN-DBS induced decreases in activity throughout the basal ganglia, whereas EPN-DBS increased activity in projection regions. While chemical inactivation of the STN or EPN with the GABAA agonist muscimol also suppressed VCMs, muscimol infusion did not mimic the changes in neuronal activity induced by DBS, suggesting that DBS is not equivalent to functional inactivation. We next examined the contribution of serotonin (5-HT) and dopamine (DA) to the anti-dyskinetic effects of DBS. Decreasing 5-HT transmission pharmacologically or with serotonergic lesions decreased VCMs. Using microdialysis and zif268 mapping, we determined that STN- but not EPN-DBS decreased 5-HT release and activity of raphe neurons. However, when the decrease in 5-HT induced by STN-DBS was prevented by pre-treating rats with fluoxetine or fenfluramine, we found that decreasing 5-HT is not necessary for the anti-dyskinetic effects of DBS. STN-DBS transiently increased striatal DA release in intact rats only, whereas EPN-DBS had no effect on DA release. Moreover, pharmacologically elevating DA levels did not suppress VCMs. Together these findings lead us to conclude that increased DA release does not contribute to the anti-dyskinetic effects of DBS. Finally, we compared depressive- and anxiety-like behaviours induced by chronic DBS of the EPN and STN, since adverse psychiatric effects of DBS have become a significant clinical concern. STN-DBS but not EPN-DBS induced depressive-like behaviour in a learned helplessness task. We established that the chronic HAL VCM model preparation may be used to explore mechanisms underlying anti-dyskinetic and psychiatric effects of DBS, and provided the first investigations into these mechanisms.

This study examined the effects of 30 minutes of cycle exercise at 65% V̇O2max on the pharmacokinetics of the S.S.R.I. sertraline. Blood samples were taken over 48 hours from 14 healthy males (23.9±2.5 years, 80.3±12.6 kilograms) following oral ingestion of a single 100 mg dose of sertraline. Participants completed two sertraline trials separated by at least two weeks; one trial while resting and the other trial with exercise as described above. With exercise, the absorption rate constant and volume of sertraline in the central compartment decreased, while the elimination half-life increased. Maximum concentration, time of maximum concentration, and area under the curve were unchanged. Fitness level had little impact on the concentration of sertraline, as compartmental modeling was unchanged when relative V̇O2max was added as a covariate. However, controlling for participant body weight improved the model estimate. These results indicate that acute aerobic exercise has the potential to change the concentration of sertraline in vivo.

Les microARNs sont des petits ARNs non codants d'environ 22 nucléotides qui régulent négativement la traduction de l'ARN messager cible (ARNm) et ont donc des fonctions cellulaires. Le microARN-16 (miR-16) est connu pour ses effets antiprolifératifs. Nous avons observé que l’expression de miR-16 est diminuée dans les cellules endothéliales humaines sénescentes et quiescentes en comparaison à des cellules prolifératives. Une analyse informatique des sites potentiels de liaison de miR-16 prévoit que GLUT-4, un transporteur du glucose insulinodépendant, pourrait être une cible potentielle du miR-16. Nous avons donc testé l'hypothèse que miR-16 régule négativement le métabolisme du glucose cellulaire. Dans des HUVEC, l'inhibition de miR-16 endogène avec des anti-miRNA oligonucléotides (AMO) augmente les niveaux protéiques de GLUT-4 de 1,7 ± 0,4 fois (p=0,0037 ; n=9). Dans des souris nourries avec un régime alimentaire normal ou riche en graisse et en sucre, l’expression de GLUT-4 dans le muscle squelettique a tendance à corréler négativement avec les niveaux de miR-16 (p=0,0998, r2=0,3866, n=4). Ces résultats suggèrent que miR-16 est un régulateur négatif de GLUT-4 et qu’il pourrait être impliqué dans la régulation du métabolisme cellulaire du glucose. / MicroRNAs are small noncoding RNAs of approximately 22 nucleotides that negatively regulate translation of the target messenger RNA (mRNA) and therefore have cellular functions. MicroRNA-16 (miR-16) is known to display anti-proliferative effects. We observed that miR-16 was down-regulated in non-proliferative human senescent endothelial cells. Computational analysis of the potential binding sites of miR-16 predicted that GLUT-4, an insulin-dependent glucose transporter, is a potential target of miR- 16. We therefore tested the hypothesis that miR-16 down-regulates cellular glucose metabolism. In HUVEC, inhibition of using anti-miRNA oligonucleotides (AMO) endogenous miR-16 up-regulated GLUT-4 protein levels 1,7 ± 0,39 folds (p=0,0037; n=9). In mice fed a regular or high fat diet, skeletal muscle expression of GLUT-4 tended to negatively correlate with miR- 16 levels (p=0,0998, r2=0,3866, n=4). These results suggest that miR-16 is a negative regulator of GLUT-4 and may be involved in the regulation of cellular glucose metabolism.

This study sought to determine the roles of D1 and D2 receptors in mediating gambling reinforcement in pathological gamblers and controls (n=24/group), and the influence of reward novelty on these effects. Subjects received D2 antagonist, haloperidol (3mg), or D1-D2 antagonist, fluphenazine (3mg) in a placebo-controlled, counterbalanced, two-session design. Incentive motivation and hedonic impact were assessed before and after a 15-min slot machine game. Haloperidol tended to increase pre-game motivation but reduce the priming effect of the slot machine, while fluphenazine increased positive mood ratings but reduced motivation to gamble. Haloperidol effects were stronger when it was received on the first session, while fluphenazine had stronger effects after prior drug-free exposure. Results suggest D1 signaling is central to reward expectancy and motivation to gamble, and that moderate stimulation increases positive affect while reducing motivation to gamble. D1 blockade may also enhance reinforcement of a familiar task by interfering with reward expectancy.